R. Donald Harvey
0000-0002-4217-1313
158 papers found
Refreshing results…
A randomized clinical trial comparing granulocyte--colony-stimulating factor administration sites for mobilization of peripheral blood stem cells for patients with hematologic malignancies undergoing autologous stem cell transplantation
Withaferin A inhibits breast cancer invasion and metastasis at sub-cytotoxic doses by inducing vimentin disassembly and serine 56 phosphorylation
Phase 1 Dose-Escalation Study of Multiple Dosing Schedules of the Investigational Drug MLN4924, a Nedd8-Activating Enzyme Inhibitor, In Patients with Relapsed and/or Refractory Multiple Myeloma or Lymphoma.
Phase I Study of Vorinostat in Patients With Advanced Solid Tumors and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group Study
A Phase I/II Trial Combining High-Dose Melphalan and Autologous Transplant with Bortezomib for Multiple Myeloma: A Dose- and Schedule-Finding Study
Phase I and Pharmacologic Study of SNS-032, a Potent and Selective Cdk2, 7, and 9 Inhibitor, in Patients With Advanced Chronic Lymphocytic Leukemia and Multiple Myeloma
Phase 1 and pharmacokinetic study of everolimus, a mammalian target of rapamycin inhibitor, in combination with docetaxel for recurrent/refractory nonsmall cell lung cancer
Safety, tolerability, and pharmacokinetics of TAK-701, a humanized anti-hepatocyte growth factor (HGF) monoclonal antibody, in patients with advanced nonhematologic malignancies: First-in-human phase I dose-escalation study.
Phase IB dose escalation study of bortezomib and sunitinib in patients with refractory solid tumors.
Combination therapy with sunitinib and bortezomib in adult patients with radioiodine refractory thyroid cancer.
Myelodysplastic syndromes and the role of iron overload
Iron overload in myelodysplastic syndromes Introduction
Through the looking glass: the evolution of erythropoiesis-stimulating Agent Use
Phase I and pharmacokinetic study of everolimus, an mTOR inhibitor, in combination with docetaxel for recurrent/refractory non-small cell lung cancer
Histological and genetic markers for non-small-cell lung cancer: Customizing treatment based on individual tumor biology
Preliminary Results of a Phase I Study of the Pan-PI3 Kinase Inhibitor SF1126 in Patients with Relapsed and Refractory Myeloma.
A Randomized Clinical Trial Comparing Cytokine Administration Sites for Mobilization of Peripheral Hematopoietic Progenitor Cells for Patients with Hematological Malignancies Undergoing Autologous Stem Cell Transplantation.
Commentary on Perrone et al.:‘Vitamin C: not for breakfast anymore… if you have myeloma’
Proportion of subjects with an ethically acceptable reason for enrolling in a phase I trial
Abstract# 3993: Using Proton MRS to predict responses of SAHA treatment in glioblastoma
Missing publications? Search for publications with a matching author name.